Evaluation of Safety and Performance of Intraoperative Detection of Light Signals During Electrosurgical Breast Cancer Resection
NCT ID: NCT06020573
Last Updated: 2024-09-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2023-09-26
2024-07-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In consequence the data should also be taken to adapt technical features according to the findings. The study results will be utilized to design and to calculate the sample size for future pivotal studies after finalizing this study and to adapt the technical features of the system and/ or device. In the future pivotal study, the effectiveness of method and the reduction in R1 resection rate will be assessed with the final goal to provide continuous or real-time information about the tissue type that is currently cut.
The primary endpoint for this first in human feasibility study is the percentage of patients with no serious adverse event related to the investigational device.
After signing the informed consent the doctor and research team will determine if the participant meets all requirements for this study. During the second visit (V2) they will receive the treatment procedure with the investigational medical device (IMD). The follow up visit (V3) will be performed up to 7 days after the treatment procedure at the day of discharge from the hospital.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Selective Sentinella Lymph Node Biopsy with Indocyanine Green in Patients with Breast Cancer
NCT06378944
Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01796041
Efficacy of OneMark Device in Identifying Breast Cancer for Surgery and Surveillance
NCT07087691
A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay
NCT01899079
The LightPath® Breast Cancer Study
NCT02666079
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intraoperative detection of light signals during electrosurgical breast cancer resection
Participants undergo electrosurgical breast cancer resection while light signals are detected intraoperatively
Clip-on electrode with fiber optics
The device will be used for tumor resection of breast cancer and for the collection of optical data that could be ultimately used for providing additional information.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clip-on electrode with fiber optics
The device will be used for tumor resection of breast cancer and for the collection of optical data that could be ultimately used for providing additional information.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Solid tumor size ≥ 15 mm at screening, on sonography imaging
3. Breast conserving surgery
4. ≥ 18 years of age
5. Ability to provide written informed consent
Exclusion Criteria
2. Bilateral breast conserving surgery
3. Invasive lobular carcinoma, DCIS, LCIS
4. Suspicion of extensive DCIS component of NST tumor
5. Diagnosis of recurrent breast cancer
6. Previous radiotherapy
7. Patient is pregnant or lactating
8. Patient is wearing active implant (cardiac pacemaker, internal defibrillator, other active implant), passive implants (hip arthroplasties, tooth implants etc.) are allowed at the discretion of the principal investigator
9. According to physicians' assessment, patient is not able to follow study protocol (e.g., due to cognitive disease) or is not able to understand the nature, objectives, benefits, implications, risks and inconveniences of the clinical investigation
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Erbe Elektromedizin GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Markus Hahn, Prof.Dr. Med.
Role: PRINCIPAL_INVESTIGATOR
Department for Women's Health, Tuebingen, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department for Women's Health
Tübingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Spether D, Scharpf M, Hennenlotter J, Schwentner C, Neugebauer A, Nussle D, Fischer K, Zappe H, Stenzl A, Fend F, Seifert A, Enderle M. Real-time tissue differentiation based on optical emission spectroscopy for guided electrosurgical tumor resection. Biomed Opt Express. 2015 Mar 24;6(4):1419-28. doi: 10.1364/BOE.6.001419. eCollection 2015 Apr 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
768/2022MP1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.